Financial reports
20-F
2023 FY
Annual report (foreign)
28 Mar 24
20-F
2022 FY
Annual report (foreign)
30 Mar 23
20-F
2021 FY
Annual report (foreign)
31 Mar 22
20-F
2020 FY
Annual report (foreign)
2 Apr 21
20-F
2019 FY
Annual report (foreign)
27 Apr 20
20-F
2018 FY
Annual report (foreign)
29 Apr 19
20-F
2017 FY
Annual report (foreign)
30 Mar 18
20-F
2016 FY
Annual report (foreign)
28 Apr 17
20-F
2015 FY
Annual report (foreign)
25 Apr 16
20-F/A
2014 FY
Annual report (foreign) (amended)
29 May 15
Current reports
6-K
Current report (foreign)
2 Apr 24
6-K
Current report (foreign)
28 Mar 24
6-K
Evogene Reports Receipt of Nasdaq Minimum Bid Price Notification
20 Mar 24
6-K
Evogene Reports Fourth Quarter and Full Year 2023 Financial Results
7 Mar 24
6-K
AgPlenus Announces Appointment of Dr. Dan Jacob Gelvan
22 Feb 24
6-K
AgPlenus Announces Licensing & Collaboration Agreement with Bayer
21 Feb 24
6-K
Biomica Successfully Completes Phase I Trial Enrollment for Microbiome-Based Immuno-Oncology Drug
17 Jan 24
6-K
Current report (foreign)
9 Jan 24
6-K
Casterra Appoints New CEO and Expands Team to Drive Growth and Innovation
19 Dec 23
6-K
Evogene Reports Third Quarter 2023 Financial Results
15 Nov 23
Registration and prospectus
424B5
Prospectus supplement for primary offering
28 Mar 24
F-3
Shelf registration (foreign)
1 Mar 24
424B5
Prospectus supplement for primary offering
18 Jul 23
424B3
Prospectus supplement
31 Mar 22
S-8
Registration of securities for employees
31 Aug 21
F-3
Shelf registration (foreign)
19 Feb 21
424B5
Prospectus supplement for primary offering
14 Jan 21
424B5
Prospectus supplement for primary offering
2 Nov 20
424B5
Prospectus supplement for primary offering
2 Sep 20
F-3
Shelf registration (foreign)
31 Jul 20
Proxies
No filings
Other
EFFECT
Notice of effectiveness
29 Mar 24
EFFECT
Notice of effectiveness
4 Mar 21
CORRESP
Correspondence with SEC
1 Mar 21
UPLOAD
Letter from SEC
24 Feb 21
EFFECT
Notice of effectiveness
11 Aug 20
CORRESP
Correspondence with SEC
6 Aug 20
UPLOAD
Letter from SEC
5 Aug 20
CT ORDER
Confidential treatment order
21 Nov 13
EFFECT
Notice of effectiveness
20 Nov 13
CORRESP
Correspondence with SEC
18 Nov 13
Ownership
SC 13G
SILVERARC CAPITAL MANAGEMENT, LLC
14 Feb 24
SC 13G/A
MACQUARIE GROUP LTD
11 Feb 22
SC 13G/A
ARK Investment Management LLC
9 Feb 22
SC 13G/A
ARK Investment Management LLC
16 Feb 21
SC 13G/A
Senvest Management, LLC
12 Feb 21
SC 13G/A
WADDELL & REED FINANCIAL INC
12 Feb 21
SC 13G/A
UBS Group AG
8 Feb 21
SC 13G/A
ALPHA CAPITAL ANSTALT
21 Jan 21
SC 13G/A
ALPHA CAPITAL ANSTALT
2 Nov 20
SC 13G
ARK Investment Management LLC
9 Oct 20